Go to deals
Healthcare

PAUL HARTMANN AG has acquired Whitestone Acquisition Corp.

November 2008 — The private shareholders of Whitestone Acquisition Corp. have sold the company to PAUL HARTMANN AG (HARTMANN). Financial details have not been disclosed.

HARTMANN, headquartered in Heidenheim, Germany, is a worldwide leader in wound management, incontinence management and risk prevention products in the operating room. Together with the existing US subsidiary, HARTMANN-Conco, Inc. in Rock Hill, South Carolina, HARTMANN consolidates its position in the nursing home and home care sector, the most important market for incontinence products. With this acquisition, the USA will become the third largest market for HARTMANN after Germany and France. The company also sees great opportunities for the establishment of system solutions for inpatient and outpatient care.

Whitestone Acquisition Corp., based in Bloomington, Indiana, is a manufacturer of high-quality adult disposable incontinence products such as briefs, liners and underpads. Formed in 1995, Whitestone annually produces and distributes products for over US$40 million. The corporation primarily serves the institutional long-term care and healthcare markets, markets which are growing 7% a year due to demographic trends.

Our role in the transaction

Oaklins' team in Germany advised HARTMANN on the acquisition of Whitestone Acquisition Corp.

Parties

Talk to the deal team

Dr. Florian von Alten

Managing Partner
Hamburg, Germany
Oaklins Germany

Related deals

Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Healthcare

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.

Learn more
Life & Mobility has attracted investor Bolster Investment Partners
Private Equity | Healthcare

Life & Mobility has attracted investor Bolster Investment Partners

Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.  

Learn more
Synergia and Bolster have secured acquisition financing for Life & Mobility
Private Equity | Healthcare

Synergia and Bolster have secured acquisition financing for Life & Mobility

Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.

Learn more